In addition to the already existing clinical development centered around rare diseases, development of oligonucleotide therapeutics for common diseases and intractable diseases such as cancer is ...
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: By Application Area, Type of Product Synthesized, Type of Oligonucleotide ...
• An estimate of the overall, installed capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain; it highlights the distribution of available ...
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from ...
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030" report has been added to ...
Oligonucleotide developers face a challenge. Traditional manufacturing methods work in the lab, however, they use toxic solvents and require extensive processing which makes them hard to scale up.
Over the past two decades, more than $22B of direct investment fueled the rapid growth of the oligonucleotide therapeutic market. To illustrate, in 2019, 163 companies were actively working on 542 ...
Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, ...
During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved siRNA therapeutic asset, inclisiran. Codexis enzymatically synthesized the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback